Carvykti denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits the Quantity of Carvykti — and Why You Can Appeal

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy for relapsed or refractory multiple myeloma. Because it is a one-time, patient-specific manufactured infusion, insurers including Aetna typically structure their coverage policy around a single lifetime administration. A quantity-limits denial usually means the claim or authorization request appeared to exceed that boundary — for example, a re-treatment request, a manufacturing lot replacement scenario, or a data-entry code mismatch.

## Why This Is Appealable

Quantity-limits denials are among the most successfully overturned on appeal when the clinical record clearly shows (a) the treatment falls within the manufacturer's and FDA-approved label's intended administration parameters and (b) the clinical circumstances justify the request. Aetna must apply its own published medical policy criteria, not a stricter standard, and every quantity decision must be clinically grounded.

## Federal Appeal Framework

• Internal appeal (Level 1): You have the right to a full-and-fair internal review under ERISA §503 (self-funded plans) or applicable state law (fully insured). Submit within the timeframe stated on your denial letter.
• External review (Level 2): Under ACA §2719, if the internal appeal is denied you may escalate to an independent external review organization (IRO). The general window is approximately four months from the original denial, though your denial letter states the exact deadline — use that date, not an estimate.
• Expedited review: If your condition is urgent or the standard timeline would seriously jeopardize your health, request expedited review in writing at the same time you file the internal appeal.

## Documentation to Gather

1. Diagnosis confirmation — pathology/cytogenetics reports confirming relapsed or refractory multiple myeloma and prior treatment history. 2. Prior-treatment history — a dated, outcome-annotated list of every prior line of therapy, sufficient to establish where Carvykti falls in the treatment sequence per the FDA-approved label. 3. Clinical rationale for the specific request — your prescriber's letter explaining precisely how the quantity requested aligns with the FDA prescribing information and Aetna's published coverage policy, with chart citations. 4. Prescriber medical-necessity letter — must address Aetna's quantity criteria point by point.

## Criteria-Mapping Structure

Pull the current Aetna clinical policy bulletin for Carvykti directly from Aetna's policy library. Copy each quantity-related criterion verbatim into a table. In the adjacent column, cite the exact chart entry (date, result, note) that satisfies it. This side-by-side format is the single most effective tool for overturning a quantity-limits denial at the internal or external level.

## Next Step

Request the denial reason code and the specific policy language Aetna applied. If Aetna cannot point to a policy provision that the request actually violates, that gap is your primary appellate argument.